Vav family exchange factors: An integrated regulatory and functional view

Small GTPases

Volumn 5, Issue 2, 2014, Pages

  Bustelo, Xosé R ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Cancer; Cardiovascular biology; Dbl homology; Disease; GDP GTP exchange factors; Immunology; Nervous system; Rho GTPases; Signaling; Therapies; Vav

Indexed keywords

GUANINE NUCLEOTIDE EXCHANGE FACTOR; UNCLASSIFIED DRUG; VAV PROTEIN; VAV1 PROTEIN; VAV2 PROTEIN; VAV3 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

CATALYSIS; CELL LINEAGE; CELL MEMBRANE; GENETIC ANALYSIS; HUMAN; IN VIVO STUDY; MOLECULAR EVOLUTION; MOLECULAR PATHOLOGY; MOLECULAR PHYLOGENY; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MOLECULAR SEQUENCE DATA; PROTO-ONCOGENE PROTEINS C-VAV; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84922232669     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: 10.4161/21541248.2014.973757     Document Type: Review

References (153)

1. Katzav S, Martin-Zanca D, Barbacid M. Vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J 1989; 8:2283-90; PMID:2477241
2. Henske EP, Short MP, Jozwiak S, Bovey CM, Ramlakhan S, Haines JL, Kwiatkowski DJ. Identification of VAV2 on 9q34 and its exclusion as the tuberous sclerosis gene TSC1. Ann Hum Genet 1995; 59:25-37; PMID:7762982; http://dxdoi.org/10.1111/j.1469-1809.1995.tb01603.x
3. Schuebel KE, Bustelo XR, Nielsen DA, Song BJ, Bar-bacid M, Goldman D, Lee IJ. Isolation and characterization of murine vav2, a member of the vav family of proto-oncogenes. Oncogene 1996; 13:363-71; PMID: 8710375
4. Movilla N, Bustelo XR. Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol Cell Biol 1999; 19:7870-85; PMID:10523675
5. Bustelo XR. Regulatory and signaling properties of the Vav family. Mol Cell Biol 2000; 20:1461-77; PMID:10669724; http://dx.doi.org/10.1128/MCB.20.5. 1461-1477.2000
6. Bustelo XR. Vav proteins, adaptors and cell signaling. Oncogene 2001; 20:6372-81; PMID:11607839; http://dx.doi.org/10.1038/sj.onc.1204780
7. Turner M, Billadeau DD. VAV proteins as signal integrators for multi-subunit immune-recognition receptors. Nat Rev Immunol 2002; 2:476-86; PMID:12094222; http://dx.doi.org/10.1038/nri840
8. Tybulewicz VL. Vav-family proteins in T-cell signalling. Curr Opin Immunol 2005; 17:267-74; PMID: 15886116; http://dx.doi.org/10.1016/j.coi.2005.04.003
9. Bustelo XR. Regulation of Vav proteins by intramolecular events. Front Biosci 2002; 7:d24-30; PMID:11779690; http://dx.doi.org/10.2741/bustelo
10. Hornstein I, Alcover A, Katzav S. Vav proteins, masters of the world of cytoskeleton organization. Cell Sig 2004; 16:1-11; PMID:14607270; http://dx.doi.org/10.1016/S0898-6568(03)00110-4
11. Bustelo XR. Vav family. In: Choy S, ed. Encyclopedia of Signaling Molecules. New York: Springer, 2012; 1963-76
12. Bustelo XR. Vav1. UCSD Nat Mol Pages 2010; http://dx.doi.org/10.1038/mp.a002360.01
13. Bustelo XR, Couceiro JR. Vav3. UCSD Nat Mol Pages 2008; http://dx.doi.org/10.1038/mp.a002362.01
14. Bustelo XR. Vav2. UCSD Nat Mol Pages 2008; http://dx.doi.org/10.1038/mp.a002361.01
15. Manning G, Young SL, Miller WT, Zhai Y. The pro-tist, Monosiga brevicollis, has a tyrosine kinase signaling network more elaborate and diverse than found in any known metazoan. Proc Natl Acad Sci USA 2008; 105:9674-9; PMID:18621719; http://dx.doi.org/10.1073/pnas.0801314105
16. Bustelo XR, Rubin SD, Suen KL, Carrasco D, Barba-cid M. Developmental expression of the vav protooncogene. Cell Growth Differ 1993; 4:297-308; PMID:8494792
17. Trenkle T, McClelland M, Adlkofer K, Welsh J. Major transcript variants of VAV3, a new member of the VAV family of guanine nucleotide exchange factors. Gene 2000; 245:139-49; PMID:10713454; http://dx.doi.org/10.1016/S0378-1119(00)00026-3
18. Zugaza JL, Lopez-Lago MA, Caloca MJ, Dosil M, Movilla N, Bustelo XR. Structural determinants for the biological activity of Vav proteins. J Biol Chem 2002; 277:45377-92; PMID:12228230; http://dx.doi.org/10.1074/jbc.M208039200
19. Ksionda O, Saveliev A, Kochl R, Rapley J, Faroudi M, Smith-Garvin JE, Wulfing C, Rittinger K, Carter T, Tybulewicz VL. Mechanism and function of Vav1 localisation in TCR signalling. J Cell Sci 2012; 125:5302-14; PMID:22956543; http://dx.doi.org/10.1242/jcs.105148
20. Yu B, Martins IR, Li P, Amarasinghe GK, Umetani J, Fernandez-Zapico ME, Billadeau DD, Machius M, Tomchick DR, Rosen MK. Structural and energetic mechanisms of cooperative autoinhibition and activation of Vav1. Cell 2010; 140:246-56; PMID: 20141838; http://dx.doi.org/10.1016/j.cell.2009.12.033
21. Rapley J, Tybulewicz VL, Rittinger K. Crucial structural role for the PH and C1 domains of the Vav1 exchange factor. EMBO Rep 2008; 9:655-61; PMID: 18511940; http://dx.doi.org/10.1038/embor.2008.80
22. Chrencik JE, Brooun A, Zhang H, Mathews, II, Hura GL, Foster SA, Perry JJ, Streiff M, Ramage P, Widmer H, et al. Structural basis of guanine nucleo-tide exchange mediated by the T-cell essential Vav1. J Mol Biol 2008; 380:828-43; PMID:18589439; http://dx.doi.org/10.1016/j.jmb.2008.05.024
23. Barreira M, Fabbiano S, Couceiro JR, Torreira E, Martinez-Torrecuadrada JL, Montoya G, Llorca O, Bustelo XR. The C-terminal SH3 domain contributes to the intramolecular inhibition of Vav family proteins. Sci Sig 2014; 7:ra35; PMID:24736456; http://dx.doi.org/10.1126/scisignal.2004993
24. Schuebel KE, Movilla N, Rosa JL, Bustelo XR. Phos-phorylation-dependent and constitutive activation of Rho proteins by wild-type and oncogenic Vav-2. EMBO J 1998; 17:6608-21; PMID:9822605; http://dx.doi.org/10.1093/emboj/17.22.6608
25. Nishida M, Nagata K, Hachimori Y, Horiuchi M, Ogura K, Mandiyan V, Schlessinger J, Inagaki F. Novel recognition mode between Vav and Grb2 SH3 domains. EMBO J 2001; 20:2995-3007; PMID: 11406576; http://dxdoi.org/10.1093/emboj/20.12.2995
26. Ogura K, Nagata K, Horiuchi M, Ebisui E, Hasuda T, Yuzawa S, Nishida M, Hatanaka H, Inagaki F. Solution structure of N-terminal SH3 domain of Vav and the recognition site for Grb2 C-terminal SH3 domain. J Biomol NMR 2002; 22:37-46; PMID: 11885979; http://dxdoi.org/10.1023/A:1013868731495
27. Crespo P, Schuebel KE, Ostrom AA, Gutkind JS, Bustelo XR. Phosphotyrosine-dependent activation of Rac-1 GDPGTP exchange by the vav proto-oncogene product. Nature 1997; 385:169-72; PMID:8990121; http://dx.doi.org/10.1038/385169a0
28. Movilla N, Dosil M, Zheng Y, Bustelo XR. How Vav proteins discriminate the GTPases Rac1 and RhoA from Cdc42. Oncogene 2001; 20:8057-65; PMID: 11781818; http://dx.doi.org/10.1038/sj.onc.1205000
29. Abe K, Rossman KL, Liu B, Ritola KD, Chiang D, Campbell SL, Burridge K, Der CJ. Vav2 is an activator of Cdc42, Rac1, and RhoA. J Biol Chem 2000; 275:10141-9; PMID:10744696; http://dx.doi.org/10.1074/jbc.275.14.10141
30. Aghazadeh B, Lowry WE, Huang XY, Rosen MK. Structural basis for relief of autoinhibition of the Dbl homology domain ofproto-oncogene Vav by tyrosine phosphorylation. Cell 2000; 102:625-33; PMID: 11007481; http://dx.doi.org/10.1016/S0092-8674(00) 00085-4
31. Couceiro JR, Martin-Bermudo MD, Bustelo XR. Phylogenetic conservation of the regulatory and functional properties of the Vav oncoprotein family. Exp Cell Res 2005; 308:364-80; PMID:15950967; http://dx.doi.org/10.1016/j.yexcr.2005.04.035
32. Razidlo GL, Schroeder B, Chen J, Billadeau DD, McNiven MA. Vav1 as a central regulator of invade-podia assembly. Curr Biol 2014; 24:86-93; PMID: 24332539; http://dx.doi.org/10.1016/j.cub.2013.11.013
33. Duan L, Raja SM, Chen G, Virmani S, Williams SH, Clubb RJ, Mukhopadhyay C, Rainey MA, Ying G, Dimri M, et al. Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration. J Biol Chem 2011;286:620-33; PMID:20940296; http://dx.doi.org/10.1074/jbc.M110.188086
34. Duan L, Chen G, Virmani S, Ying G, Raja SM, Chung BM, Rainey MA, Dimri M, Ortega-Cava CF, Zhao X, et al. Distinct roles for Rho versus RacCdc42 GTPases downstream ofVav2 in regulating mammary epithelial acinar architecture. J Biol Chem 2010; 285:1555-68; PMID:19826000; http://dx.doi.org/10.1074/jbc.M109.057976
35. Ambrogio C, Voena C, Manazza AD, Martinengo C, Costa C, Kirchhausen T, Hirsch E, Inghirami G, Chiarle R The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res 2008; 68:8899-907; PMID:18974134 http://dx-doi-org/10-1158/0008-5472-CAN-08-2568
36. Aoki K, Nakamura T, Fujikawa K, Matsuda M. Local phosphatidylinositol 3,4,5-trisphosphate accumulation recruits Vav2 and Vav3 to activate Rac1Cdc42 and initiate neurite outgrowth in nerve growth factor-stimulated PC12 cells. Mol Biol Cell 2005; 16:220717; PMID:15728722; http://dx-doi-org/10-1091/mbc-E04-10-0904
37. Tu S, Wu WJ, Wang J, Cerione RA. Epidermal growth factor-dependent regulation ofCdc42 is mediated by the Src tyrosine kinase. J Biol Chem 2003; 278:49293-300; PMID:14506284; http://dx-doi-org/10-1074/jbc-M307021200
38. Gakidis MA, Cullere X, Olson T, Wilsbacher JL, Zhang B, Moores SL, Ley K, Swat W, Mayadas T, Brugge JS. Vav GEFs are required for beta2 integrin-dependent functions of neutrophils. J Cell Biol 2004; 166:273-82; PMID:15249579; http://dx-doi-org/10-1083/jcb-200404166
39. Zeng R, Cannon JL, Abraham RT, Way M, Billadeau DD, Bubeck-Wardenberg J, Burkhardt JK-SLP-76 coordinates Nck-dependent Wiskott-Aldrich syndrome protein recruitment with Vav-1Cdc42-depen-dent Wiskott-Aldrich syndrome protein activation at the T cell-APC contact site. J Immunol 2003; 171:1360-8; PMID:12874226; http://dx-doi-org/10-4049/jimmunol-171-3-1360
40. Ardouin L, Bracke M, Mathiot A, Pagakis SN, Norton T, Hogg N, Tybulewicz VL. Vav1 transduces TCR signals required for LFA-1 function and cell polarization at the immunological synapse. Eur J Immunol 2003; 33:790-7; PMID:12616499; http://dx-doi-org/10-1002/eji-200323858
41. Fackler OT, Luo W, Geyer M, Alberts AS, Peterlin BM. Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions, Mol Cell 1999; 3:729-39; PMID:10394361; http://dx-doi-org/10-1016/S1097-2765(01)80005-8
42. Liu BP, Burridge K., Vav2 activates Rac1, Cdc42, and RhoA downstream from growth factor receptors but not beta1 integrins. Mol Cell Biol 2000; 20:7160-9; PMID:10982832; http://dx-doi-org/10-1128/MCB-20-19-7160-7169-2000
43. Booden MA, Campbell SL, Der CJ. Critical but distinct roles for the pleckstrin homology and cysteine-rich domains as positive modulators ofVav2 signaling and transformation. Mol Cell Biol 2002; 22: 2487-97; PMID:11909943; http://dx-doi-org/10-1128/MCB-22-8-2487-2497-2002
44. Wu J, Katzav S, Weiss A. A functional T-cell receptor signaling pathway is required for p95vav activity. MolCellBiol1995; 15:4337-46; PMID:7623828
45. Kuhne MR, Ku G, Weiss A. A guanine nucleotide exchange factor-independent function of Vav1 in transcriptional activation. J Biol Chem 2000; 275:2185-90; PMID:10636924; http://dx-doi-org/10-1074/jbc-275-3-2185
46. Zhou Z, Yin J, Dou Z, Tang J, Zhang C, Cao Y. The calponin homology domain of Vav1 associates with calmodulin and is prerequisite to T cell antigen receptor-induced calcium release in Jurkat T lymphocytes, J Biol Chem 2007; 282:23737-44; PMID:17550897; http://dx-doi-org/10-1074/jbc-M702975200
47. Saveliev A, Vanes L, Ksionda O, Rapley J, Smerdon SJ, Rittinger K, Tybulewicz VL. Function of the nucleotide exchange activity of Vav1 in T cell development and activation. Sci Sig 2009; 2:ra83; PMID:20009105; http://dx-doi-org/10-1126/scisignal-2000420
48. Reynolds LF, Smyth LA, Norton T, Freshney N, Downward J, Kioussis D, Tybulewicz VL-Vav1 transduces T cell receptor signals to the activation of phospholipase C-gammal via phosphoinositide 3-kinase-dependent and -independent pathways. J Exp Med 2002; 195:1103-14; PMID:ll9944l6; http://dx.doi.org/10.1084/jem.20011663
49. Doody GM, Billadeau DD, Clayton E, Hutchings A, Berland R, McAdam S, Leibson PJ, Turner M. Vav-2 controls NFAT-dependent transcription in B-but not T-lymphocytes. EMBO J 2000; 19:6173-84; PMID:11080163; http://dx.doi.org/10.1093/emboj/19.22.6173
50. del Pozo MA, Schwartz MA, Hu J, Kiosses WB, Alt-man A, Villalba M. Guanine exchange-dependent and -independent effects of Vav1 on integrin-induced T cell spreading. J Immunol 2003; 170:41-7; PMID: 12496381; http://dx.doi.org/10.4049/jimmunol.170.1.41
51. Sylvain NR, Nguyen K, Bunnell SC. Vav1-mediated scaffolding interactions stabilize SLP-76 microclusters and contribute to antigen-dependent T cell responses. Sci Sig 2011; 4:ra14; PMID:21386095; http://dx.doi.org/10.1126/scisignal.2001178
52. Jacob CO, Eisenstein M, Dinauer MC, Ming W, Liu Q, John S, Quismorio FP Jr, Reiff A, Myones BL, Kaufman KM, et al. Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase. Proc Natl Acad Sci USA 2012; 109:E59-67; PMID:22203994; http://dx.doi.org/10.1073/pnas.1113251108
53. Citterio C, Menacho-Marquez M, Garcia-Escudero R, Larive RM, Barreiro O, Sanchez-Madrid F, Para-mio JM, Bustelo XR. The Rho exchange factors Vav2 and Vav3 control a lung metastasis-specific transcrip-tional program in breast cancer cells. Sci Sig 2012; 5: ra71; PMID:23033540; http://dx.doi.org/10.1126/scisignal.2002962
54. Zenker S, Panteleev-Ivlev J, Wirtz S, Kishimoto T, Waldner MJ, Ksionda O, Tybulewicz VL, Neurath MF, Atreya I. A key regulatory role for Vav1 in controlling lipopolysaccharide endotoxemia via macro-phage-derived IL-6. J Immunol 2014; 192:2830-6; PMID:24532586; http://dx.doi.org/10.4049/jimmunol. 1300157
55. Houlard M, Arudchandran R, Regnier-Ricard F, Germani A, Gisselbrecht S, Blank U, Rivera J, Varin-Blank N. Vav1 is a component of transcriptionally active complexes. J Exp Med 2002; 195:1115-27; PMID:11994417; http://dx.doi.org/10.1084/jem. 20011701
56. Brugnoli F, Lambertini E, Varin-Blank N, Piva R, Marchisio M, Grassilli S, Miscia S, Capitani S, Ber-tagnolo V. Vav1 and PU.1 are recruited to the CD11b promoter in APL-derived promyelocytes: role of Vav1 in modulating PU.1-containing complexes during ATRA-induced differentiation. Exp Cell Res 2010; 316:38-47; PMID:19747912; http://dx.doi.org/10.1016/j.yexcr.2009.09.004
57. Lyons LS, Burnstein KL. Vav3, a Rho GTPase gua-nine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol 2006; 20:1061-72; PMID: 16384856; http://dx.doi.org/10.1210/me.2005-0346
58. Liu Y, Wu X, Dong Z, Lu S. The molecular mechanism ofVav3 oncogene on upregulation ofandrogen receptor activity in prostate cancer cells. Int J Oncol 2010; 36:623-33; PMID:20126983; http://dx.doi.org/10.3892/ijo_00000644
59. Peacock SO, Fahrenholtz CD, Burnstein KL. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Mol Endocrinol 2012; 26:196779; PMID:23023561; http://dx.doi.org/10.1210/me.2012-1165
60. Wu F, Peacock SO, Rao S, Lemmon SK, Burnstein KL. Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth. J Biol Chem 2013; 288:5463-74; PMID: 23281476;http://dx-doi-org/10-1074/jbc-M112-390963
61. Vigorito E, Kovesdi D, Turner M. Synergistic activa-tionofPKD bythe B cell antigen receptor andCD19 requires PI3K, Vav1 and PLCgamma. Cell Sig 2006; 18:1455-60; PMID:16380231; http://dx-doi-org/10-1016/j-cellsig-2005-11-008
62. Caloca MJ, Zugaza JL, Bustelo XR. Mechanistic analysis of the amplification and diversification events induced by Vav proteins in B-lymphocytes. J Biol Chem 2008; 283:36454-64; PMID:18974050; http://dx-doi-org/10-1074/jbc-M803814200
63. Caloca MJ, Zugaza JL, Matallanas D, Crespo P, Bus-telo XR. Vav mediates Ras stimulation by direct activation of the GDPGTP exchange factor Ras GRP1. EMBO J 2003; 22:3326-36; PMID:12839994; http://dx-doi-org/10-1093/emboj/cdg316
64. Zugaza JL, Caloca MJ, Bustelo XR. Inverted signaling hierarchy between RAS and RAC in T-lymphocytes. Oncogene 2004; 23:5823-33; PMID:15184873; http://dx-doi-org/10-1038/sj-onc-1207768
65. Costello PS, Walters AE, Mee PJ, Turner M, Reynolds LF, Prisco A, Sarner N, Zamoyska R, Tybule-wicz VL. The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-kappaB pathways. Proc Natl Acad Sci USA 1999; 96:3035-40; PMID:10077632; http://dx-doi-org/10-1073/pnas-96-6-3035
66. Reynolds LF, de Bettignies C, Norton T, Beeser A, Chernoff J, Tybulewicz VL. Vav1 transduces T cell receptor signals to the activation of the RasERK path-wayvia LAT, Sos, and RasGRP1. J Biol Chem 2004; 279:18239-46; PMID:14764585; http://dx-doi-org/10-1074/jbc-M400257200
67. Colucci F, Rosmaraki E, Bregenholt S, Samson SI, Di Bartolo V, Turner M, Vanes L, Tybulewicz V, Di Santo JP. Functional dichotomy in natural killer cell signaling: Vav1-dependent and -independent mechanisms. J Exp Med 2001; 193:1413-24; PMID: 11413196; http://dx-doi-org/10-1084/jem-193-12-1413
68. Manetz TS, Gonzalez-Espinosa C, Arudchandran R, Xirasagar S, Tybulewicz V, Rivera J-Vav1 regulates phospholipase cgamma activation and calcium responses in mast cells. Mol Cell Biol 2001; 21:376-374; PMID:11340169; http://dx-doi-org/10-1128/MCB-21-11-3763-3774-2001
69. Faccio R, Teitelbaum SL, Fujikawa K, Chappel J, Zal-lone A, Tybulewicz VL, Ross FP, Swat W-Vav3 regulates osteoclast function and bone mass. Nat Med 2005; 11:284-90; PMID:15711558; http://dx-doi-org/10-1038/nm1194
70. Sauzeau V, Sevilla MA, Montero MJ, Bustelo XR. The RhoRac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells. J Clin Invest 2010; 120:315-30; PMID:20038798; http://dx-doi-org/10-1172/JCI38356
71. Norman KR, Fazzio RT, Mellem JE, Espelt MV, Strange K, Beckerle MC, Maricq AV. The RhoRac-family guanine nucleotide exchange factor VAV-1 regulates rhythmic behaviors in C-elegans. Cell 2005; 123:119-32; PMID:16213217; http://dx-doi-org/10-1016/j-cell-2005-08-001
72. Moores SL, Selfors LM, Fredericks J, Breit T, Fujikawa K, Alt FW, Brugge JS, Swat W. Vav family proteins couple to diverse cell surface receptors. Mol Cell Biol 2000; 20:6364-73; PMID:10938113; http://dx-doi-org/10-1128/MCB-20-17-6364-6373-2000
73. Rodrigues L, Pires de Miranda M, Caloca MJ, Bustelo XR, Simas JP. ActivationofVavbythegammaherpes-virus M2 protein contributes to the establishment of viral latency in B lymphocytes. J Virol 2006; 80:6123-35; PMID:16731951; http://dx-doi-org/10-1128/JVI-02700-05
74. Gomez TS, Hamann MJ, McCarney S, Savoy DN, Lubking CM, Heldebrant MP, Labno CM, McKean DJ, McNiven MA, Burkhardt JK, et al. Dynamin 2 regulates T cell activation by controlling actin polymerization at the immunological synapse. Nat Immunol 2005; 6:261-70; PMID:15696170; http://dx.doi.org/10.1038/ni 1168
75. Malartre M, Ayaz D, Amador FF, Martin-Bermudo MD. The guanine exchange factor vav controls axon growth and guidance during Drosophila development. J Neurosci 2010; 30:2257-67; PMID:20147552; http://dx.doi.org/10.1523/JNEUROSCI.1820-09.2010
76. Fernandez-Espartero CH, Ramel D, Farago M, Malartre M, Luque CM, Limanovich S, Katzav S, Emery G, Martin-Bermudo MD. GTP exchange factor Vav regulates guided cell migration by coupling guidance receptor signalling to local Rac activation. J Cell Sci 2013; 126:2285-93; PMID:23525006; http://dx.doi.org/10.1242/jcs.124438
77. Ruiz S, Santos E, Bustelo XR. The use of knockout mice reveals a synergistic role of the Vav1 and Rasgrf2 gene deficiencies in lymphomagenesis and metastasis. PloS One 2009; 4:e8229; PMID:20011522; http://dx.doi.org/10.1371/journal.pone.0008229
78. Sauzeau V, Jerkic M, Lopez-Novoa JM, Bustelo XR. Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice. Mol Biol Cell 2007;18:943-52; PMID:17202406; http://dx.doi.org/10.1091/mbc.E06-09-0877
79. Quevedo C, Sauzeau V, Menacho-Marquez M, Castro-Castro A, Bustelo XR. Vav3-deficient mice exhibit a transient delay in cerebellar development. Mol Biol Cell 2011; 21:1125-39; PMID:20089829; http://dx.doi.org/10.1091/mbc.E09-04-0292
80. Sauzeau V, Horta-Junior JAC, Riolobos AS, Fernandez G, Sevilla MA, Lopez DE, Montero MJ, Rico B, Bustelo XR. Vav3 is involved in GABAergic axon guidance events important for the proper function of brainstem neurons controlling cardiovascular, respiratory, and renal parameters. Mol Biol Cell 2010;21:4251-63; PMID:20926682; http://dx.doi.org/10.1091/mbc.E10-07-0639
81. Guyenet PG. The sympathetic control ofblood pressure. Nat Rev Neurosci 2006; 7:335-46; PMID: 16760914; http://dx.doi.org/10.1038/nrn1902
82. Sauzeau V, Sevilla MA, Rivas-Elena JV, de Alava E, Montero MJ, Lopez-Novoa JM, Bustelo XR. Vav3 proto-oncogene deficiency leads to sympathetic hyper-activity and cardiovascular dysfunction. Nat Med 2006; 12:841-5; PMID:16767097; http://dx.doi.org/10.1038/nm1426
83. Menacho-Marquez M, Nogueiras R, Fabbiano S, Sau-zeau V, Al-Massadi O, Dieguez C, Bustelo XR. Chronic sympathoexcitation through loss of Vav3, a Rac1 activator, results in divergent effects on metabolic syndrome and obesity depending on diet. Cell Metab 2013; 18:199-211; PMID:23931752; http://dx.doi.org/10.1016/j.cmet.2013.07.001
84. Cowan CW, Shao YR, Sahin M, Shamah SM, Lin MZ, Greer PL, Gao S, Griffith EC, Brugge JS, Green-berg ME. Vav family GEFs link activated Ephs to endocytosis and axon guidance. Neuron 2005; 46:205-17; PMID:15848800; http://dx.doi.org/10.1016/j.neuron.2005.03.019
85. Hale CF, Dietz KC, Varela JA, Wood CB, Zirlin BC, Leverich LS, Greene RW, Cowan CW. Essential role for vav Guanine nucleotide exchange factors in brain-derived neurotrophic factor-induced dendritic spine growth and synapse plasticity. J Neurosci 2011; 31:12426-36; PMID:21880903; http://dx.doi.org/10.1523/JNEUROSCI.0685-11.2011
86. Hunter SG, Zhuang G, Brantley-Sieders D, Swat W, Cowan CW, Chen J. Essential role of Vav family gua-nine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Mol Cell Biol 2006; 26:483042; PMID:16782872; http://dx.doi.org/10.1128/MCB.02215-05
87. Liu JY, Seno H, Miletic AV, Mills JC, Swat W, Stappenbeck TS. Vav proteins are necessary for correct differentiation of mouse cecal and colonic enterocytes. J Cell Sci 2009; 122:324-34; PMID:19139088; http://dx.doi.org/10.1242/jcs.033720
88. Ruiz S, Santos E, Bustelo XR. RasGRF2, a guanosine nucleotide exchange factor for Ras GTPases, participates in T-cell signaling responses. Mol Cell Biol 2007; 27:8127-42; PMID:17923690; http://dx-doi-org/10-1128/MCB-00912-07
89. Lawson CD, Donald S, Anderson KE, Patton DT, Welch HC. P-Rex1 and Vav1 cooperate in the regulation offormyl-methionyl-leucyl-phenylalanine-depen-dent neutrophil responses. J Immunol 2011; 186:1467-76; PMID:21178006; http://dx-doi-org/10-4049/jimmunol-1002738
90. Lopez-Lago M, Lee H, Cruz C, Movilla N, Bustelo XR. Tyrosine phosphorylation mediates both activation and downmodulation ofthe biological activity of Vav. Mol Cell Biol 2000; 20:1678-91; PMID: 10669745; http://dx-doi-org/10-1128/MCB-20-5-1678-1691-2000
91. Katzav S, Cleveland JL, Heslop HE, Pulido D. Loss of theamino-terminalhelix-loop-helixdomainofthevav proto-oncogene activates its transforming potential Mol Cell Biol 1991; 11:1912-20; PMID:2005887
92. Ming W, Li S, Billadeau DD, Quilliam LA, Dinauer MC. The Rac effector p67phox regulates phagocyte NADPH oxidase by stimulating Vav1 guanine nucle-otide exchange activity. Mol Cell Biol 2007; 27:31223; PMID:17060455; http://dx-doi-org/10-1128/MCB-00985-06
93. Moarefi I, LaFevre-Bernt M, Sicheri F, Huse M, Lee CH, Kuriyan J, Miller WT. Activation ofthe Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 1997; 385:650-3; PMID:9024665; http://dx-doi-org/10-1038/385650a0
94. Bustelo XR, Ledbetter JA, Barbacid M. Product ofvav proto-oncogene defines a new class of tyrosine protein kinase substrates. Nature 1992; 356:68-71; PMID: 1311423; http://dx-doi-org/10-1038/356068a0
95. Margolis B, Hu P, Katzav S, Li W, Oliver JM, Ullrich A, Weiss A, Schlessinger J. Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs. Nature 1992; 356:71-4; PMID:1531699; http://dx-doi-org/10-1038/356071a0
96. Kant S, Swat W, Zhang S, Zhang ZY, Neel BG, Fla-vell RA, Davis RJ. TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway. Genes Dev 2011; 25:2069-78; PMID: 21979919;http://dx-doi-org/10-1101/gad-17224711
97. Menacho-Marquez M, Garcia-Escudero R, Ojeda V, Abad A, Delgado P, Costa C, Ruiz S, Alarcon B, Para-mio JM, Bustelo XR. The Rho exchange factors Vav2 and Vav3 favor skin tumor initiation and promotion by engaging extracellular signaling loops. PLoS Biol 2013; 11:e1001615; PMID:23935450; http://dx-doi-org/10-1371/journal-pbio-1001615
98. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-depen-dent endocytosis of VE-cadherin. Nat Cell Biol 2006; 8:1223-34; PMID:17060906; http://dx-doi-org/10-1038/ncb1486
99. Valls G, Codina M, Miller RK, Del Valle-Perez B, Vinyoles M, Caelles C, McCrea PD, Garcia de Herreros A, Dunach M. Upon Wnt stimulation, Rac1 activation requires Rac1 and Vav2 binding to p120. catenin. J Cell Sci 2012; 125:5288-301; PMID: 22946057; http://dx-doi-org/10-1242/jcs-101030
100. Weng WK, Jarvis L, LeBien TW. Signaling through CD19 activates Vavmitogen-activated protein kinase pathway and induces formation of a CD19Vavphos-phatidylinositol 3-kinase complex in human B cell precursors. J Biol Chem 1994; 269:32514-21; PMID:7528218
101. O'Rourke LM, Tooze R, Turner M, Sandoval DM, Carter RH, Tybulewicz VL, Fearon DT. CD19 as a membrane-anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav. Immunity 1998; 8:635-45; PMID:9620684; http://dx-doi-org/10-1016/S1074-7613(00)80568-3
102. Son M, Park I, Lee OH, Rhee I, Park C, Yun Y. LIME mediates immunological synapse formation through activation of VAV. Mol Cells 2012; 33:40714; PMID:22395814; http://dx.doi.org/10.1007/s10059-012-0011-8
103. Johmura S, Oh-hora M, Inabe K, Nishikawa Y, Haya-shi K, Vigorito E, Kitamura D, Turner M, Shingu K, Hikida M, et al. Regulation of Vav localization in membrane rafts by adaptor molecules Grb2 and BLNK. Immunity 2003; 18:777-87; PMID: 12818159; http://dx.doi.org/10.1016/S1074-7613(03)00139-0
104. Wu J, Motto DG, Koretzky GA, Weiss A. Vav and SLP-76 interact and functionally cooperate in IL-2 gene activation. Immunity 1996; 4:593-602; PMID: 8673706; http://dx.doi.org/10.1016/S1074-7613(00) 80485-9
105. Tuosto L, Michel F, Acuto O. p95vav associates with tyrosine-phosphorylated SLP-76 in antigen-stimulated T cells. J Exp Med 1996; 184:1161-6; PMID:9064333; http://dx.doi.org/10.1084/jem.184. 3.1161
106. Lindholm CK, Henriksson ML, Hallberg B, Welsh M. Shb links SLP-76 and Vav with the CD3 complex in Jurkat T cells. Eur J Biochem 2002; 269:3279-88; PMID:12084069; http://dx.doi.org/10.1046/j.1432-1033.2002.03008.x
107. Pauker MH, Hassan N, Noy E, Reicher B, Barda-Saad M. Studying the dynamics of SLP-76, Nck, and Vav1 multimolecular complex formation in live human cells with triple-color FRET. Sci Sig 2012; 5: rs3; PMID:22534133; http://dx.doi.org/10.1126/scisignal.2002423
108. Barda-Saad M, Shirasu N, Pauker MH, Hassan N, Perl O, Balbo A, Yamaguchi H, Houtman JC, Appella E, Schuck P, et al. Cooperative interactions at the SLP-76 complex are critical for actin polymerization. EMBO J 2010; 29:2315-28; PMID:20562827; http://dx.doi.org/10.1038/emboj.2010.133
109. Charvet C, Canonigo AJ, Billadeau DD, Altman A. Membrane localization and function of Vav3 in T cells depend on its association with the adapter SLP-76. J Biol Chem 2005; 280:15289-99; PMID: 15708849; http://dx.doi.org/10.1074/jbc.M500275200
110. Zhang W, Irvin BJ, Trible RP, Abraham RT, Samel. son LE. Functional analysis of LAT in TCR-mediated signaling pathways using a LAT-deficient Jurkat cell line. Int Immunol 1999; 11:943-50; PMID: 10360968; http://dx.doi.org/10.1093/intimm/11.6.943
111. Lahesmaa R, Allsup A, Soderberg C, Jackman J, Fin-dell P, Peltz G. Modulation of the Grb2-associated protein complex in human CD4+ T cells by receptor activation. J Immunol 1995; 155:3815-22; PMID:7561087
112. Blanchet F, Cardona A, Letimier FA, Hershfield MS, Acuto O. CD28 costimulatory signal induces protein arginine methylation in T cells. J Exp Med 2005; 202:371-7; PMID:16061726; http://dx.doi.org/10.1084/jem.20050176
113. Choudhary C, Kumar C, Gnad F, Nielsen ML, Reh-man M, Walther TC, Olsen JV, Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325:834-40; PMID: 19608861; http://dx.doi.org/10.1126/science.1175371
114. Puga I, Rao A, Macian F. Targeted cleavage of signaling proteins by caspase 3 inhibits T cell receptor signaling in anergic T cells. Immunity 2008; 29:193204; PMID:18701083; http://dx.doi.org/10.1016/j.immuni.2008.06.010
115. Hofmann TG, Hehner SP, Droge W, Schmitz ML. Caspase-dependent cleavage and inactivation of the Vav1 proto-oncogene product during apoptosis prevents IL-2 transcription. Oncogene 2000; 19:115363; PMID:10713703; http://dx.doi.org/10.1038/sj.onc.1203406
116. Razidlo GL, Wang Y, Chen J, Krueger EW, Billadeau DD, McNiven MA. Dynamin 2 potentiates invasive migration of pancreatic tumor cells through stabilization of the Rac1 GEF Vav1. Dev Cell 2013; 24:573-85; PMID:23537630; http://dx.doi.org/10.1016/j.devcel.2013.02.010
117. Yoo AS, Greenwald I. LIN-12Notch activation leads to microRNA-mediated down-regulation of Vav in C. elegans. Science 2005; 310:1330-3; PMID:16239437; http://dx.doi.org/10.1126/science.1119481
118. Wang R, Zhao N, Li S, Fang JH, Chen MX, Yang J, Jia WH, Yuan Y, Zhuang SM. MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology 2013; 58:642-53; PMID:23468064; http://dx.doi.org/10.1002/hep.26373
119. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009; 35:85667; PMID:19782034; http://dx.doi.org/10.1016/j.molcel.2009.09.006
120. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R, Smyrk TC, Chari ST, Urrutia R, Billadeau DD. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 2005; 7:39-49; PMID: 15652748; http://dx.doi.org/10.1016/j.ccr.2004.11.024
121. Carvajal-Gonzalez JM, Mulero-Navarro S, Roman AC, Sauzeau V, Merino JM, Bustelo XR, Fernandez-Salguero PM. The dioxin receptor regulates the constitutive expression of the vav3 proto-oncogene and modulates cell shape and adhesion. Mol Biol Cell 2009; 20:1715-27; PMID:19158396; http://dx.doi.org/10.1091/mbc.E08-05-0451
122. Ilan L, Katzav S. Human Vav1 expression in hemato-poietic and cancer cell lines is regulated by c-Myb and by CpG methylation. PloS One 2012; 7:e29939; PMID:22253833; http://dx.doi.org/10.1371/journal.pone.0029939
123. Sauzeau V, Carvajal-Gonzalez JM, Riolobos AS, Sevilla MA, Menacho-Marquez M, Roman AC, Abad A, Montero MJ, Fernandez-Salguero P, Bustelo XR. Transcriptional factor aryl hydrocarbon receptor (Ahr) controls cardiovascular and respiratory functions by regulating the expression of the Vav3 protooncogene. J Biol Chem 2011; 286:2896-909; PMID:21115475; http://dx.doi.org/10.1074/jbc. M110.187534
124. Gulbins E, Coggeshall KM, Baier G, Telford D, Langlet C, Baier-Bitterlich G, Bonnefoy-Berard N, Burn P, Wittinghofer A, Altman A. Direct stimulation of Vav guanine nucleotide exchange activity for Ras by phorbol esters and diglycerides. Mol Cell Biol 1994; 14:4749-58; PMID:7516472
125. Han J, Luby-Phelps K, Das B, Shu X, Xia Y, Mosteller RD, Krishna UM, Falck JR, White MA, Broek D. Role ofsubstrates and products ofPI 3-kinase in regulating activation of Rac-related guanosine triphospha-tases by Vav. Science 1998; 279:558-60; PMID: 9438848; http://dx.doi.org/10.1126/science.279.5350.558
126. Kazanietz MG, Bustelo XR, Barbacid M, Kolch W, Mischak H, Wong G, Pettit GR, Bruns JD, Blumberg PM. Zinc finger domains and phorbol ester pharma-cophore. Analysis of binding to mutated form of protein kinase C zeta and the vav and c-raf protooncogene products. J Biol Chem 1994; 269:11590-4; PMID:8157692
127. Geczy T, Peach ML, El Kazzouli S, Sigano DM, Kang JH, Valle CJ, Selezneva J, Woo W, Kedei N, Lewin NE, et al. Molecular basis for failure of "atypical" C1 domain of Vav1 to bind diacylglycerolphorbol ester. J Biol Chem 2012; 287:13137-58; PMID:22351766; http://dx.doi.org/10.1074/jbc.M111.320010
128. Park WS, Heo WD, Whalen JH, O'Rourke NA, Bryan HM, Meyer T, Teruel MN. Comprehensive identification of PIP3-regulated PH domains from C. elegans to H. sapiens by model prediction and live imaging. Mol Cell 2008; 30:381-92; PMID:18471983; http://dx.doi.org/10.1016/j.molcel.2008.04.008
129. Isakoff SJ, Cardozo T, Andreev J, Li Z, Ferguson KM, Abagyan R, Lemmon MA, Aronheim A, Skolnik EY. Identification and analysis of PH domain-containing targets of phosphatidylinositol 3-kinase using a novel in vivo assay in yeast. EMBO J 1998; 17:5374-87; PMID:9736615; http://dx-doi-org/10-1093/emboj/17-18-5374
130. Inabe K, Ishiai M, Scharenberg AM, Freshney N, Downward J, Kurosaki T. Vav3 modulates B cell receptor responses by regulating phosphoinositide 3-kinase activation. J Exp Med 2002; 195:189-200; PMID:11805146; http://dx-doi-org/10-1084/jem-20011571
131. Bassermann F, Jahn T, Miething C, Seipel P, Bai RY, Coutinho S, Tybulewicz VL, Peschel C, Duyster J-Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway. J Biol Chem 2002; 277:12437-45; PMID:11790798; http://dx-doi-org/10-1074/jbc-M112397200
132. Harnois T, Constantin B, Rioux A, Grenioux E, Kit-zis A, Bourmeyster N. Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl. Oncogene 2003; 22:6445-54; PMID: 14508524; http://dx-doi-org/10-1038/sj-onc-1206626
133. Patel V, Rosenfeldt HM, Lyons R, Servitja JM, Bus-telo XR, Siroff M, Gutkind JS. Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFRVav2 signaling axis involved in cell invasion. Carcinogenesis 2007; 28:1145-52; PMID:17234718; http://dx-doi-org/10-1093/carcin/bgm008
134. Levaot N, Voytyuk O, Dimitriou I, Sircoulomb F, Chandrakumar A, Deckert M, Krzyzanowski PM, Scotter A, Gu S, Janmohamed S, et al. Loss of Tank-yrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell 2011; 147:1324-39; PMID:22153076; http://dx-doi-org/10-1016/j-cell-2011-10-045
135. Pires de Miranda M, Alenquer M, Marques S, Rodrigues L, Lopes F, Bustelo XR, Simas JP. The Gammaherpesvirus m2 Protein Manipulates the Fyn-Vav Pathway through a Multidocking Mechanism of Assembly. PloS One 2008; 3:e1654; PMID: 18301737;http://dx-doi-org/10-1371/journal-pone-0001654
136. Pires de Miranda M, Lopes FB, McVey CE, Bustelo XR, Simas JP. Role ofSrc homology domain binding in signaling complexes assembled by the murid gamma-herpesvirus M2 protein. J Biol Chem 2013; 288:3858-70; PMID:23258536; http://dx-doi-org/10-1074/jbc-M112-439810
137. Jagodic M, Colacios C, Nohra R, Dejean AS, Beyeen AD, Khademi M, Casemayou A, Lamouroux L, Duthoit C, Papapietro O, et al. A role for VAV1 in experimental autoimmune encephalomyelitis and multiple sclerosis. Sci Transl Med 2009; 1:10ra21; PMID:20368159; http://dx-doi-org/10-1126/scitranslmed-3000278
138. Aleksic B, Kushima I, Hashimoto R, Ohi K, Ikeda M, Yoshimi A, Nakamura Y, Ito Y, Okochi T, Fukuo Y, et al. Analysis of the VAV3 as candidate gene for schizophrenia: evidences from voxel-based morphom-etry and mutation screening. Schizoph Bull 2013; 39:720-8; PMID:22416266; http://dx-doi-org/10-1093/schbul/sbs038
139. Eriksson N, Tung JY, Kiefer AK, Hinds DA, Francke U, Mountain JL, Do CB-Novel associations for hypo-thyroidism include known autoimmune risk loci. PloS One 2012; 7:e34442; PMID:22493691; http://dx-doi-org/10-1371/journal-pone-0034442
140. Fujikawa K, Iwata T, Inoue K, Akahori M, Kadotani H, Fukaya M, Watanabe M, Chang Q, Barnett EM, Swat W-VAV2 and VAV3 as candidate disease genes for spontaneous glaucoma in mice and humans. PloS One 2010; 5:e9050; PMID:20140222; http://dx-doi-org/10-1371/journal-pone-0009050
141. Shi D, Takano Y, Nakazawa T, Mengkegale M, Yoko-kura S, Nishida K, Fuse N, Molecular genetic analysis of primary open-angle glaucoma, normal tension glaucoma, and developmental glaucoma for the VAV2 and VAV3 gene variants in Japanese subjects. Biochem Biophys Res Comm 2013; 432:509-12; PMID:23402756; http://dx.doi.org/10.1016/j-bbrc.2013.02.003
142. Rao KN, Kaur I, Parikh RS, Mandal AK, Chandrase-khar G, Thomas R, Chakrabarti S. Variations in NTF4, VAV2, and VAV3 genes are not involved with primary open-angle and primary angle-closure glaucomas in an indian population. Invest Ophthalmol Vis Sci 2010; 51:4937-41; PMID:20463313; http://dx.doi.org/10.1167/iovs.10-5553
143. Martin H, Mali RS, Ma P, Chatterjee A, Ramdas B, Sims E, Munugalavadla V, Ghosh J, Mattingly RR, Visconte V, et al. Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. J Clin Invest 2013; 123:4449-63; PMID:24091327; http://dx.doi.org/10.1172/JCI67509
144. Chang KH, Sanchez-Aguilera A, Shen S, Sengupta A, Madhu MN, Ficker AM, Dunn SK, Kuenzi AM, Arnett JL, Santho RA, et al. Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogen-esis, proliferation and survival. Blood 2012; 120:80011; PMID:22692505; http://dx.doi.org/10.1182/blood-2011-06-361709
145. Rahaman SO, Li W, Silverstein RL. Vav Guanine nucleotide exchange factors regulate atherosclerotic lesion development in mice. Arterioscler Thromb Vasc Biol 2013; 33:2053-7; PMID:23825362; http://dx.doi.org/10.1161/ATVBAHA.113.301414
146. Chen K, Li W, Major J, Rahaman SO, Febbraio M, Silverstein RL. Vav guanine nucleotide exchange factors link hyperlipidemia and a prothrombotic state. Blood 2011; 117:5744-50; PMID:21427288; http://dx.doi.org/10.1182/blood-2009-01-201970
147. Rahaman SO, Swat W, Febbraio M, Silverstein RL. Vav family Rho guanine nucleotide exchange factors regulate CD36-mediated macrophage foam cell formation. J Biol Chem 2011; 286:7010-7; PMID: 21209086;http://dx.doi.org/10.1074/jbc.M110.192450
148. Haubert D, Li J, Saveliev A, Calzascia T, Sutter E, Metzler B, Kaiser D, Tybulewicz VL, Weckbecker G. Vav1 GEF activity is required for T cell mediated allo-graft rejection. Transpl Immunol 2012; 26:212-9; PMID:22456277; http://dx.doi.org/10.1016/j.trim. 2012.03.003
149. Yi F, Xia M, Li N, Zhang C, Tang L, Li PL. Contribution ofguanine nucleotide exchange factor Vav2 to hyperhomocysteinemic glomerulosclerosis in rats. Hypertension 2009; 53:90-6; PMID:19029489; http://dx.doi.org/10.1161/HYPERTENSIONAHA.108.115675
150. Andre G, Sandoval JE, Retailleau K, Loufrani L, Tou-maniantz G, Offermanns S, Rolli-Derkinderen M, Loirand G, Sauzeau V. Smooth muscle specific Rac1 deficiency induces hypertension by preventing p116RIP3-dependent RhoA inhibition. J Am Heart Ass 2014; 3:e000852; PMID:24938713; http://dx.doi.org/10.1161/JAHA.114.000852
151. Fabbiano S, Menacho-Marquez M, Sevilla MA, Albarran-Juairez J, Zheng Y, Offermanns S, Montero MJ, Bustelo XR. Genetic dissection ofthe Vav2-Rac1 signaling axis in vascular smooth muscle cells. Mol Cell Biol 2014; PMID:25288640; http://dx.doi.org/10.1128/MCB.01066-14
152. Vigil D, Cherfils J, Rossman KL, Der CJ. Ras super-family GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 2010; 10:842-57; PMID:21102635; http://dx.doi.org/10.1038/nrc2960
153. Shang X, Marchioni F, Evelyn CR, Sipes N, Zhou X, Seibel W, Wortman M, Zheng Y. Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors. Proc Natl Acad Sci USA 2013; 110:3155-60; PMID:23382194; http://dx.doi.org/10.1073/pnas.1212324110